Faron Pharmaceuticals Oy FARN

First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumorsTURKU, FI / ACCESS Newswire / October 1, 2026 / Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that the first patient has been dosed in the Phase 1/2 BLAZE investigator-initiated trial.

TURKU, FI / ACCESS Newswire / September 30, 2026 / (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company and Heights Capital Management, Inc. ("HCM") have mutually agreed to defer the amortisation payment of the First and Second Tranche Bonds (as defined below) scheduled for 2 October 2026.

TURKU, FI / ACCESS Newswire / September 17, 2026 / (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: OY 1b.

Faron announces R&D Day to be held on 8 October 2026TURKU, FI / ACCESS Newswire / September 10, 2026 / Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that it will host an R&D Day for investors, analysts and media on 8 October 2026 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST).

Faron Pharmaceuticals Oy (FRA:4FR) reports robust frontline data and a strengthened cash position, setting the stage for the BEXERA trial readout in late 2027.

Faron Pharmaceuticals Limited (AIM:FARN) is set to start its phase IIb BEXERA trial for blood cancer drug bexmarilimab in the second half of this year. It'll test the drug in 90 patients across the US, Europe and the UK, funded by a €40 million rights issue. Central Asia Metals PLC (AIM:CAML, OTC:CAMLF) has nearly doubled first-half earnings on higher copper and zinc prices plus higher output. Profit before tax jumped 203%, and the interim dividend's been lifted to 8p. Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has completed drone testing with QinetiQ on its sulfur battery cathode material. Cel

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026 TURKU, FI / ACCESS Newswire / August 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage ...

Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. For patients with biallelic ...

Investigators update from BLAZE in checkpoint-resistant solid tumors highlights continued progress across Faron's expanding Investigator-Initiated Trial (IIT) portfolio TURKU, FI / ACCESS Newswire / July 13, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), ...

TURKU, FI / ACCESS Newswire / July 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context ...